Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

31 results
Display

Primary pulmonary epithelioid inflammatory myofibroblastic sarcoma: a rare entity and a literature review

Singh P, Nambirajan A, Gaur MK, Raj R, Kumar S, Malik PS, Jain D

Epithelioid inflammatory myofibroblastic sarcoma (EIMS) is an aggressive subtype of inflammatory myofibroblastic tumor (IMT) harboring anaplastic lymphoma kinase (ALK) gene fusions and is associated with high risk of local recurrence...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Lorlatinib Therapy for Rapid and Dramatic Control of Brain and Spinal Leptomeningeal Metastases From ALK-Positive Lung Adenocarcinoma

Sun MG, Kim IY, Kim YJ, Jung TY, Moon KS, Jung S, Oh IJ, Kim YC, Choi YD

We report a patient with severe neurological deterioration due to leptomeningeal metastases involving brain and spinal cord from anaplastic lymphoma kinase (ALK)-positive lung adenocarcinoma, managed rapidly and successfully with lorlatinib...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Anaplastic Lymphoma Kinase Positive Large B-cell Lymphoma Mimicking Metastatic Carcinoma of the Cervical Lymph Node from an Unknown Primary Lesion

Kim SW, Lee K, Kim BH, Kim EJ

Anaplastic lymphoma kinase positive large B-cell lymphoma (ALK+LBCL) is a rare subtype of B-cell lymphoma with aggressive features and a poor prognosis. The rarity of this disease and similarity of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A case of concomitant EGFR/ALK alteration against a mutated EGFR background in early-stage lung adenocarcinoma

Lee KC, Koh J, Chung DH, Jeon YK

Rare cases of lung adenocarcinoma (LUAD) with concomitant epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) translocation have been reported. However, their clonal and evolutional relationship remains...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Detection of Targetable Genetic Alterations in Korean Lung CancerPatients: A Comparison Study of Single-Gene Assays andTargeted Next-Generation Sequencing

Park E, Shim HS

Purpose Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and ROS proto-oncogene 1 (ROS1) are ‘must-test’ biomarkers in the molecular diagnostics of advanced- stage lung cancer patients. Although single-gene assays are currently...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of CD 30+/ALK− Primary Systemic Anaplastic Large Cell Lymphoma Presenting a Sporotrichoid Pattern

Shin YB, Jo JW, Kim CY

  • KMID: 2502807
  • Korean J Dermatol.
  • 2020 Mar;58(3):200-203.
Systemic anaplastic large cell lymphoma (ALCL) is an aggressive CD30-positive non-Hodgkin lymphoma. The most common clinical manifestations of systemic ALCL are solitary or multiple large nodular tumoral lesions confined to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Characteristics of Renal Cell Carcinoma Harboring TPM3-ALK Fusion

Woo CG, Yun SJ, Son SM, Lim YH, Lee OJ

The World Health Organization 2016 edition assigned anaplastic lymphoma kinase (ALK) rearrangement-associated renal cell carcinoma (ALK-RCC) as an emerging renal tumor entity. Identifying ALK-RCC is important because ALK inhibitors have...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer

Ock CY, Yoo SH, Keam B, Kim M, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS

BACKGROUND/AIMS: Although crizotinib is standard chemotherapy for advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), clinical factors affecting progression-free survival (PFS) have not been reported. The purpose of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer

Kim SJ, Kim S, Kim DW, Kim M, Keam B, Kim TM, Lee Y, Koh J, Jeon YK, Heo DS

PURPOSE: The purpose of this study was to evaluate the relationships between the resistance of anaplastic lymphoma kinase (ALK)‒positive non-small cell lung cancer (NSCLC) to ALK inhibitors and the programmed...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Crizotinib in Combination with Everolimus Synergistically Inhibits Proliferation of Anaplastic Lymphoma Kinase‒Positive Anaplastic Large Cell Lymphoma

Xu W, Kim JW, Jung WJ, Koh Y, Yoon SS

PURPOSE: Anaplastic large cell lymphoma (ALCL) is a rare aggresive non-Hodgkin lymphoma, of which over 50% of cases have an aberrant nucleophosmin (NPM)‒anaplastic lymphoma kinase (ALK) fusion protein. Both mechanistic...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
ALK Protein Expression Is Related to Neuroblastoma Aggressiveness But Is Not Independent Prognostic Factor

Lee JW, Park SH, Kang HJ, Park KD, Shin HY, Ahn HS

PURPOSE: In this study, anaplastic lymphoma kinase (ALK) mutation and amplification, ALK protein expression, loss of the nuclear alpha thalassemia/mental retardation syndrome X-linked (ATRX) protein, and telomerase reverse transcriptase (TERT)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Anaplastic lymphoma kinase (ALK)-expressing Lung Adenocarcinoma with Combined Neuroendocrine Component or Neuroendocrine Transformation: Implications for Neuroendocrine Transformation and Response to ALK-tyrosine Kinase Inhibitors

Sim J, Kim H, Hyeon J, Choi YL, Han J

BACKGROUND: Anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) are usually effective in lung adenocarcinoma patients with anaplastic lymphoma kinase (ALK) rearrangement. However, even after a good response to ALK-TKI therapy,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer

Jo J, Kim SH, Kim YJ, Lee J, Kim M, Keam B, Kim TM, Kim DW, Heo DS, Chung JH, Jeon YK, Lee JS

PURPOSE: Previous retrospective studies suggest that anaplastic lymphoma kinase (ALK) mutation-positive (ALK+) non-small cell lung cancer (NSCLC) patients are sensitive to pemetrexed. To determine its efficacy, we retrospectively evaluated clinical...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Molecular Targeted Therapy in Modern Oncology: Imaging Assessment of Treatment Response and Toxicities

Krajewski , Braschi-Amirfarzan M, DiPiro PJ, Jagannathan JP, Shinagare

Oncology is a rapidly evolving field with a shift toward personalized cancer treatment. The use of therapies targeted to the molecular features of individual tumors and the tumor microenvironment has...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
CD30-Positive Anaplastic Lymphoma Kinase-Negative Systemic Anaplastic Large-Cell Lymphoma in a 9-Year-Old Boy

Kim JE, Oh EH, Ro YS, Ko JY

Anaplastic large-cell lymphoma (ALCL) is a CD30-positive T-cell/null-cell lymphoma that is clinically classified into either primary cutaneous ALCL or systemic ALCL (S-ALCL) sub-types. Because 90% of childhood S-ALCL cases are...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases

Lee T, Lee B, Choi YL, Han J, Ahn MJ, Um SW

BACKGROUND: Although epidermal growth factor receptor (EGFR), v-Ki-ras2 Kirsten rat sarcoma viral oncogene (KRAS), and anaplastic lymphoma kinase (ALK) mutations in non-small cell lung cancer (NSCLC) were thought to be...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
SEC31A-ALK Fusion Gene in Lung Adenocarcinoma

Kim RN, Choi YL, Lee MS, Lira ME, Mao M, Mann D, Stahl J, Licon A, Choi SJ, Vrancken M, Han J, Wlodarska , Kim J

Anaplastic lymphoma kinase (ALK) fusion is a common mechanism underlying pathogenesis of non-small cell lung carcinoma (NSCLC) where these rearrangements represent important diagnostic and therapeutic targets. In this study, we...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Uterine Cervix Metastasis in Lung Adenocarcinoma with Anaplastic Lymphoma Kinase Rearrangement

Choi S, Park CK, Kim SY, Yoon HK, Ro SM, Nam Y

The importance of anaplastic lymphoma kinase (ALK) as an oncogene in non-small cell lung cancer (NSCLC) has emerged as a major concern due to a dramatic clinical effect of targeted...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Analysis of Histologic Features Suspecting Anaplastic Lymphoma Kinase (ALK)-Expressing Pulmonary Adenocarcinoma

Choi IH, Kim DW, Ha SY, Choi YL, Lee HJ, Han J

BACKGROUND: Since 2007 when anaplastic lymphoma kinase (ALK) rearrangements were discovered in non-small cell lung cancer, the ALK gene has received attention due to ALK-targeted therapy, and a notable treatment...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer

Lee JK, Kim DW, Keam B, Kim TM, Lee SH, Kim YJ, Heo DS

PURPOSE: To investigate the impact of targeted treatment on direct medical costs of patients with advanced non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: Medical records of 108 stage IIIB/IV NSCLC...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr